Asunaprevir (BioDeep_00000685078)
代谢物信息卡片
Asunaprevir
化学式: C35H46ClN5O9S (747.2704616000001)
中文名称: 阿那匹韦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
InChI: InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AP - Antivirals for treatment of hcv infections
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134723
- KEGGdrug: D10093
- PubChem: 16076883
- DrugBank: DB11586
- ChEMBL: CHEMBL2105735
- CAS: 630420-16-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yun-Sook Lim, Lap P Nguyen, Gun-Hee Lee, Sung-Geun Lee, Kwang-Soo Lyoo, Bumseok Kim, Soon B Hwang. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Molecules and cells.
2021 Sep; 44(9):688-695. doi:
10.14348/molcells.2021.0076. [PMID: 34518443] - Kota Kurosaki, Yoshihiro Uesawa. Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
Biomolecules.
2021 06; 11(7):. doi:
10.3390/biom11070944. [PMID: 34202146] - Hirohito Yoneyama, Asahiro Morishita, Hisakazu Iwama, Koji Fujita, Takahiro Masaki, Joji Tani, Tomoko Tadokoro, Takako Nomura, Teppei Sakamoto, Kyoko Oura, Kei Takuma, Mai Nakahara, Shima Mimura, Akihiro Deguchi, Makoto Oryu, Kunihiko Tsutsui, Takashi Himoto, Kunitada Shimotohno, Takaji Wakita, Hideki Kobara, Tsutomu Masaki. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Journal of gastroenterology and hepatology.
2021 Apr; 36(4):1126-1135. doi:
10.1111/jgh.15224. [PMID: 32839985] - Li-Qiang Sun, Eric Mull, Stanley D'Andrea, Barbara Zheng, Sheldon Hiebert, Eric Gillis, Michael Bowsher, Sarkunam Kandhasamy, Venkata Rao Baratam, Sunitha Puttaswamy, Nagalakshmi Pulicharla, Sureshbabu Vishwakrishnan, Subba Reddy, Ravi Trivedi, Sarmistha Sinha, Sankar Sivaprasad, Abhijith Rao, Salil Desai, Kaushik Ghosh, Rushith Anumula, Amit Kumar, Ramkumar Rajamani, Ying-Kai Wang, Hua Fang, Arvind Mathur, Richard Rampulla, Tatyana A Zvyaga, Kathy Mosure, Susan Jenkins, Paul Falk, Debarati M Tagore, Chaoqun Chen, Kishore Rendunchintala, James Loy, Nicholas A Meanwell, Fiona McPhee, Paul M Scola. Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Journal of medicinal chemistry.
2020 12; 63(23):14740-14760. doi:
10.1021/acs.jmedchem.0c01296. [PMID: 33226226] - Chung-Feng Huang, Ming-Lung Yu. Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Kidney international.
2020 03; 97(3):615. doi:
10.1016/j.kint.2019.10.033. [PMID: 32087891] - Yuhei Saito, Michio Imamura, Takuro Uchida, Mitsutaka Osawa, Yuji Teraoka, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Masahiro Serikawa, Hiroshi Aikata, Hiromi Abe-Chayama, C Nelson Hayes, Kazuaki Chayama. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Journal of medical virology.
2020 02; 92(2):210-218. doi:
10.1002/jmv.25602. [PMID: 31584207] - Emanuela Zappulo, Riccardo Scotto, Antonio Riccardo Buonomo, Alberto Enrico Maraolo, Biagio Pinchera, Ivan Gentile. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Expert opinion on pharmacotherapy.
2020 Feb; 21(3):261-273. doi:
10.1080/14656566.2019.1697674. [PMID: 31914336] - Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Kuan-Yu Chen, Yu-Min Ko, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.
Journal of gastroenterology and hepatology.
2020 Jan; 35(1):151-156. doi:
10.1111/jgh.14815. [PMID: 31373037] - Hong Xiao, Jun Chen, Jiangrong Wang, Juhua Li, Feia Yang, Hongzhou Lu. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Medicine.
2019 Jul; 98(30):e16524. doi:
10.1097/md.0000000000016524. [PMID: 31348267] - Keizo Kato, Noritomo Shimada, Masanori Atsukawa, Hiroshi Abe, Norio Itokawa, Yoshihiro Matsumoto, Rie Agata, Akihito Tsubota. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
PloS one.
2019; 14(7):e0219022. doi:
10.1371/journal.pone.0219022. [PMID: 31291311] - Elizabeth J Fay, Stephanie L Aron, Ian A Stone, Barbara M Waring, Richard K Plemper, Ryan A Langlois. Engineered Small-Molecule Control of Influenza A Virus Replication.
Journal of virology.
2019 01; 93(1):. doi:
10.1128/jvi.01677-18. [PMID: 30282710] - Hawwa Alao, Maggie Cam, Chithra Keembiyehetty, Fang Zhang, Elisavet Serti, Daniel Suarez, Heiyoung Park, Nicolaas H Fourie, Elizabeth C Wright, Wendy A Henderson, Qisheng Li, T Jake Liang, Barbara Rehermann, Marc G Ghany. Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Hepatology (Baltimore, Md.).
2018 12; 68(6):2078-2088. doi:
10.1002/hep.29921. [PMID: 29704252] - Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Hidenori Toyoda, Takashi Kumada, Masashi Hattori, Yoshiaki Katano, Hidemi Goto. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Journal of viral hepatitis.
2018 12; 25(12):1446-1451. doi:
10.1111/jvh.12967. [PMID: 29993164] - Takayo Ueno, Mayu Osawa, Yasuhiko Imai, Hiroki Ishikawa, Tushar Garimella. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Journal of clinical pharmacology.
2018 11; 58(11):1479-1488. doi:
10.1002/jcph.1262. [PMID: 30063245] - Mayu Osawa, Takayo Ueno, Hiroki Ishikawa, Yasuhiko Imai, Tushar Garimella. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Journal of clinical pharmacology.
2018 11; 58(11):1468-1478. doi:
10.1002/jcph.1274. [PMID: 30063254] - Noboru Harada, Tomoharu Yoshizumi, Toru Ikegami, Shinji Itoh, Norihiro Furusho, Masaki Kato, Shinji Shimoda, Takasuke Fukuhara, Yuji Soejima, Yoshihiko Maehara. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Anticancer research.
2018 Sep; 38(9):5513-5520. doi:
10.21873/anticanres.12885. [PMID: 30194210] - NULL. 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Clinical and molecular hepatology.
2018 09; 24(3):169-229. doi:
10.3350/cmh.2018.1004. [PMID: 30092624] - Satoshi Takakusagi, Ken Sato, Yuhei Suzuki, Yuichi Yamazaki, Takashi Kosone, Satoru Kakizaki, Motoyasu Kusano, Hitoshi Takagi. Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.
Internal medicine (Tokyo, Japan).
2018 Aug; 57(15):2189-2195. doi:
10.2169/internalmedicine.9624-17. [PMID: 29526955] - Yuji Teraoka, Takuro Uchida, Michio Imamura, Nobuhiko Hiraga, Mitsutaka Osawa, Hiromi Kan, Yuhei Saito, Masataka Tsuge, Hiromi Abe-Chayama, C Nelson Hayes, Grace Naswa Makokha, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
The Journal of general virology.
2018 08; 99(8):1058-1065. doi:
10.1099/jgv.0.001091. [PMID: 29916799] - Takeshi Hirayama, Tadashi Ikegami, Akira Honda, Teruo Miyazaki, Sho-Ichiro Yara, Motoyuki Kohjima, Makoto Nakamuta, Yasushi Matsuzaki. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Internal medicine (Tokyo, Japan).
2018 May; 57(9):1219-1227. doi:
10.2169/internalmedicine.9479-17. [PMID: 29279486] - Fumitaka Suzuki, Naoya Hatanaka, Etsuya Bando, Koji Nakamura, Akira Komoto. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Hepatology international.
2018 May; 12(3):244-253. doi:
10.1007/s12072-018-9872-z. [PMID: 29900486] - Subraya Krishna Holla, Harish A Rao, Damodara Shenoy, Archith Boloor, Manaswitha Boyanagari. The role of fresh frozen plasma in reducing the volume of anti-snake venom in snakebite envenomation.
Tropical doctor.
2018 Apr; 48(2):89-93. doi:
10.1177/0049475518756083. [PMID: 29393003] - Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Gut and liver.
2018 Mar; 12(2):201-207. doi:
10.5009/gnl17179. [PMID: 29212314] - Michael Bowsher, Sheldon Hiebert, Rongti Li, Alan X Wang, Jacques Friborg, Fei Yu, Dennis Hernandez, Ying-Kai Wang, Herbert Klei, Ramkumar Rajamani, Kathy Mosure, Jay O Knipe, Nicholas A Meanwell, Fiona McPhee, Paul M Scola. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
Bioorganic & medicinal chemistry letters.
2018 01; 28(1):43-48. doi:
10.1016/j.bmcl.2017.11.005. [PMID: 29162454] - Yoshihito Uchida, Kayoko Naiki, Jun-Ichi Kouyama, Kayoko Sugawara, Masamitsu Nakao, Daisuke Motoya, Mie Inao, Nobuaki Nakayama, Yukinori Imai, Tomoaki Tomiya, Satoshi Mochida. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
PloS one.
2018; 13(10):e0205600. doi:
10.1371/journal.pone.0205600. [PMID: 30308053] - Goki Suda, Norihiro Furusyo, Hidenori Toyoda, Yoshiiku Kawakami, Hiroki Ikeda, Michihiro Suzuki, Keiko Arataki, Nami Mori, Keiji Tsuji, Yoshio Katamura, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Noritomo Shimada, Atsushi Hiraoka, Sho Yamsaki, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, Mineo Kudo, Atsushi Nagasaka, Ken Furuya, Yoshiya Yamamoto, Kanji Kato, Yoshiyuki Ueno, Etsuko Iio, Yasuhito Tanaka, Masayuki Kurosaki, Takashi Kumada, Kazuaki Chayama, Naoya Sakamoto. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Journal of gastroenterology.
2018 01; 53(1):119-128. doi:
10.1007/s00535-017-1353-y. [PMID: 28560477] - Qisheng Li, Brianna Lowey, Catherine Sodroski, Siddharth Krishnamurthy, Hawwa Alao, Helen Cha, Stephan Chiu, Ramy El-Diwany, Marc G Ghany, T Jake Liang. Cellular microRNA networks regulate host dependency of hepatitis C virus infection.
Nature communications.
2017 11; 8(1):1789. doi:
10.1038/s41467-017-01954-x. [PMID: 29176620] - Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Hidemi Goto, Yoshiki Hirooka. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
Journal of gastroenterology and hepatology.
2017 Nov; 32(11):1879-1886. doi:
10.1111/jgh.13779. [PMID: 28258705] - Norihiko Morisawa, Yohei Koshima, Jun-Ichi Satoh, Yukio Maruyama, Satoru Kuriyama, Takashi Yokoo, Morimasa Amemiya. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Clinical and experimental nephrology.
2017 Oct; 21(5):818-824. doi:
10.1007/s10157-016-1348-7. [PMID: 27771774] - Akihiro Tamori, Hoang Hai, Sawako Uchida-Kobayashi, Masaru Enomoto, Ritsuzo Kozuka, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Yuga Teranishi, Kanako Yoshida, Hiroyasu Morikawa, Yoshiki Murakami, Norifumi Kawada. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
Annals of hepatology.
2017 Sep; 16(5):734-741. doi:
10.5604/01.3001.0010.2732. [PMID: 28809743] - K Koshino, H Ushigome, K Masuda, T Matsuyama, S Harada, T Nakamura, S Nobori, T Iida, N Yoshimura. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Transplantation proceedings.
2017 Jun; 49(5):1053-1055. doi:
10.1016/j.transproceed.2017.03.051. [PMID: 28583525] - Daisuke Endo, Kenichi Satoh, Noritomo Shimada, Atsushi Hokari, Yoshio Aizawa. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
World journal of gastroenterology.
2017 Apr; 23(13):2355-2364. doi:
10.3748/wjg.v23.i13.2355. [PMID: 28428715] - Yuki Nakamura, Michio Imamura, Yoshiiku Kawakami, Yuji Teraoka, Kana Daijo, Fumi Honda, Kei Morio, Tomoki Kobayashi, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, C Nelson Hayes, Daiki Miki, Hidenori Ochi, Kazuaki Chayama. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
Journal of medical virology.
2017 04; 89(4):665-671. doi:
10.1002/jmv.24679. [PMID: 27602542] - Elisavet Serti, Heiyoung Park, Meghan Keane, Ashley C O'Keefe, Elenita Rivera, T Jake Liang, Marc Ghany, Barbara Rehermann. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Gut.
2017 04; 66(4):724-735. doi:
10.1136/gutjnl-2015-310033. [PMID: 26733671] - Timothy Eley, Tushar Garimella, Wenying Li, Richard J Bertz. Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.
Clinical pharmacology in drug development.
2017 Mar; 6(2):195-200. doi:
10.1002/cpdd.315. [PMID: 28263460] - Kei Morio, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Tomoki Kobayashi, Satoe Yokoyama, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Grace Naswa Makokha, C Nelson Hayes, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Kazuaki Chayama. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Journal of gastroenterology and hepatology.
2017 Mar; 32(3):645-650. doi:
10.1111/jgh.13511. [PMID: 27513614] - Yugo Kai, Hayato Hikita, Naoki Morishita, Kazuhiro Murai, Tasuku Nakabori, Sadaharu Iio, Hideki Hagiwara, Yasuharu Imai, Shinji Tamura, Syusaku Tsutsui, Masafumi Naito, Meiko Nishiuchi, Yasuteru Kondo, Takanobu Kato, Hiroshi Suemizu, Ryoko Yamada, Tsugiko Oze, Takayuki Yakushijin, Naoki Hiramatsu, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Scientific reports.
2017 01; 7(?):41660. doi:
10.1038/srep41660. [PMID: 28134353] - Hiromi Kan, Michio Imamura, Takuro Uchida, Nobuhiko Hiraga, C Nelson Hayes, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Grace Naswa Makokha, Sajeda Chowdhury, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
The Journal of infectious diseases.
2016 Dec; 214(11):1687-1694. doi:
10.1093/infdis/jiw437. [PMID: 27651415] - Hiroko Nagata, Mina Nakagawa, Yuki Nishimura-Sakurai, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Fumio Goto, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Naoko Tojo, Shuji Tohda, Yasuhiro Asahina, Mamoru Watanabe. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Hepatology international.
2016 Nov; 10(6):956-964. doi:
10.1007/s12072-016-9754-1. [PMID: 27435935] - Y Kawakami, M Imamura, H Ikeda, M Suzuki, K Arataki, M Moriishi, N Mori, K Kokoroishi, Y Katamura, T Ezaki, T Ueno, K Ide, T Masaki, H Ohdan, K Chayama. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
Journal of viral hepatitis.
2016 11; 23(11):850-856. doi:
10.1111/jvh.12553. [PMID: 27346670] - George Lau, Yves Benhamou, Guofeng Chen, Jin Li, Qing Shao, Dong Ji, Fan Li, Bing Li, Jialiang Liu, Jinlin Hou, Jian Sun, Cheng Wang, Jing Chen, Vanessa Wu, April Wong, Chris L P Wong, Stella T Y Tsang, Yudong Wang, Leda Bassit, Sijia Tao, Yong Jiang, Hui-Mien Hsiao, Ruian Ke, Alan S Perelson, Raymond F Schinazi. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
The lancet. Gastroenterology & hepatology.
2016 10; 1(2):97-104. doi:
10.1016/s2468-1253(16)30015-2. [PMID: 27917405] - Sai-Nan Pi, You-Peng Chen. [Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2016 Aug; 36(8):1163-4. doi:
NULL. [PMID: 27578593] - Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Koichi Takaguchi, Toru Ishikawa, Kunihiko Tsuji, Mikio Zeniya, Etsuko Iio, Yasuhito Tanaka. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Journal of gastroenterology.
2016 Jul; 51(7):741-7. doi:
10.1007/s00535-016-1174-4. [PMID: 26872889] - Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Journal of medical virology.
2016 Mar; 88(3):506-11. doi:
10.1002/jmv.24360. [PMID: 26292191] - Hamza Kandoussi, Hao Jiang, Jianing Zeng, Naiyu Zheng, Pathanjali Kadiyala, Timothy Eley, Bing He, Tushar Garimella, Roger Demers, Laura Cojocaru, Anne-Françoise Aubry, Mark E Arnold. A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis.
2016 Feb; 119(?):145-51. doi:
10.1016/j.jpba.2015.11.028. [PMID: 26683987] - Michelle Spaan, Gertine van Oord, Kim Kreefft, Jun Hou, Bettina E Hansen, Harry L A Janssen, Robert J de Knegt, Andre Boonstra. Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
The Journal of infectious diseases.
2016 Jan; 213(2):216-23. doi:
10.1093/infdis/jiv391. [PMID: 26223768] - Hideaki Kinugasa, Fusao Ikeda, Kouichi Takaguchi, Chizuru Mori, Takehiro Matsubara, Hidenori Shiraha, Akinobu Takaki, Yoshiaki Iwasaki, Shinichi Toyooka, Kazuhide Yamamoto. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Antiviral therapy.
2016; 21(1):37-44. doi:
10.3851/imp2976. [PMID: 26115551] - Yu Zhang, Ying Cao, Renwen Zhang, Xiaxia Zhang, Haiying Lu, Chihong Wu, Na Huo, Xiaoyuan Xu. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
PloS one.
2016; 11(11):e0165658. doi:
10.1371/journal.pone.0165658. [PMID: 27812165] - Jiachang Gong, Timothy Eley, Bing He, Vinod Arora, Thomas Philip, Hao Jiang, John Easter, W Griffith Humphreys, Ramaswamy A Iyer, Wenying Li. Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2016; 46(1):52-64. doi:
10.3109/00498254.2015.1048487. [PMID: 26153443] - Timothy Eley, Tushar Garimella, Wenying Li, Richard J Bertz. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Clinical pharmacokinetics.
2015 Dec; 54(12):1205-22. doi:
10.1007/s40262-015-0299-6. [PMID: 26177803] - Kathleen W Mosure, Jay O Knipe, Marc Browning, Vinod Arora, Yue-Zhong Shu, Thomas Phillip, Fiona Mcphee, Paul Scola, Anand Balakrishnan, Matthew G Soars, Kenneth Santone, Michael Sinz. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Journal of pharmaceutical sciences.
2015 Sep; 104(9):2813-23. doi:
10.1002/jps.24356. [PMID: 25631585] - Hao Jiang, Hamza Kandoussi, Jianing Zeng, Jian Wang, Roger Demers, Timothy Eley, Bing He, Richard Burrell, John Easter, Pathanjali Kadiyala, Janice Pursley, Laura Cojocaru, Chanda Baker, John Ryan, Anne-Françoise Aubry, Mark E Arnold. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Journal of pharmaceutical and biomedical analysis.
2015 Mar; 107(?):409-18. doi:
10.1016/j.jpba.2015.01.027. [PMID: 25676854] - T Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, A D Rodrigues, R J Bertz. Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.
Clinical pharmacology and therapeutics.
2015 Feb; 97(2):159-66. doi:
10.1002/cpt.4. [PMID: 25670521] - Timothy Eley, Bing He, Ih Chang, Elizabeth Colston, Michael Child, William Bedford, Hamza Kandoussi, Claudio Pasquinelli, Thomas C Marbury, Richard J Bertz. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Antiviral therapy.
2015; 20(1):29-37. doi:
10.3851/imp2773. [PMID: 24704773] - Kayo Sugimoto, Soo Ryang Kim, Soo Ki Kim, Susumu Imoto, Madoka Tohyama, Ke Ih Kim, Aya Ohtani, Takashi Hatae, Yoshihiko Yano, Masatoshi Kudo, Yoshitake Hayashi. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Oncology.
2015; 89 Suppl 2(?):42-6. doi:
10.1159/000440630. [PMID: 26584035] - Nobuhisa Akamatsu, Yasuhiko Sugawara, Norihiro Kokudo. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Expert review of anti-infective therapy.
2015; 13(11):1307-17. doi:
10.1586/14787210.2015.1091724. [PMID: 26414905] - Long Yuan, Hao Jiang, Zheng Ouyang, Yuan-Qing Xia, Jianing Zeng, Qianping Peng, Robert W Lange, Yuzhong Deng, Mark E Arnold, Anne-Françoise Aubry. A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2013 Mar; 921-922(?):81-6. doi:
10.1016/j.jchromb.2013.01.029. [PMID: 23435345] - Fiona McPhee, Amy K Sheaffer, Jacques Friborg, Dennis Hernandez, Paul Falk, Guangzhi Zhai, Steven Levine, Susan Chaniewski, Fei Yu, Diana Barry, Chaoqun Chen, Min S Lee, Kathy Mosure, Li-Qiang Sun, Michael Sinz, Nicholas A Meanwell, Richard J Colonno, Jay Knipe, Paul Scola. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Antimicrobial agents and chemotherapy.
2012 Oct; 56(10):5387-96. doi:
10.1128/aac.01186-12. [PMID: 22869577]